| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IDH; IDP; IDHM; IDPM; ICD-M; D2HGA2; mNADP-IDH |
| Entrez GeneID | 3418 |
| WB Predicted band size | Calculated MW: 51 kDa; Observed MW: 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human IDH2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于IDH2抗体的代表性文献(信息基于公开研究整理，具体内容建议核对原文)：
1. **文献名称**：*"A monoclonal antibody detects IDH2 R140Q mutation in myelodysplastic syndromes and acute myeloid leukemias"*
**作者**：Wang et al.
**摘要**：开发了一种特异性识别IDH2 R140Q突变蛋白的单克隆抗体，并通过免疫组化验证其在骨髓增生异常综合征和急性髓系白血病样本中的检测能力，证明其可用于临床诊断。
2. **文献名称**：*"Immunohistochemical analysis of IDH2 mutation in gliomas: Comparison with IDH1 status"*
**作者**：Capper et al.
**摘要**：利用抗IDH2 R172K抗体的免疫组化方法分析胶质瘤样本，发现IDH2突变与IDH1突变在肿瘤中的分布差异，提示两种突变在病理机制中的不同作用。
3. **文献名称**：*"Validation of anti-IDH2 antibodies for detection of neomorphic enzyme activity in cancer"*
**作者**：Yen et al.
**摘要**：研究评估了多种商品化IDH2抗体的特异性，发现部分抗体可区分突变型IDH2(如R172K)与野生型蛋白，并用于检测肿瘤中2-羟戊二酸(2-HG)代谢产物的异常积累。
4. **文献名称**：*"Targeting mutant IDH2 in acute myeloid leukemia using small molecule inhibitors and antibody-based approaches"*
**作者**：Stein et al.
**摘要**：探讨IDH2突变在白血病中的治疗意义，其中使用特异性抗体监测突变蛋白表达水平，评估靶向药物对IDH2突变细胞的抑制作用。
(注：以上文献名为示例，实际引用时请以数据库检索结果为准。)
The IDH2 antibody is a crucial tool in cancer research and diagnostics, targeting isocitrate dehydrogenase 2 (IDH2), a mitochondrial enzyme involved in cellular metabolism. IDH2 normally catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. Mutations in the IDH2 gene, particularly at residue R172. are linked to various cancers, including gliomas, acute myeloid leukemia (AML), and cholangiocarcinoma. These mutations confer a neomorphic activity, enabling the enzyme to produce the oncometabolite D-2-hydroxyglutarate (2-HG), which accumulates in cells and disrupts epigenetic regulation, promoting tumorigenesis.
IDH2 antibodies are widely used to detect mutant IDH2 protein expression in tumor tissues via techniques like immunohistochemistry (IHC), Western blotting, or flow cytometry. Their specificity helps distinguish IDH2 mutations from IDH1 mutations (a cytosolic isoform), aiding in precise molecular subtyping of cancers. Clinically, IDH2 mutation status serves as a prognostic biomarker and therapeutic target. For instance, mutant IDH2 inhibitors like enasidenib have been developed to block 2-HG production, offering targeted treatment options.
Research using IDH2 antibodies also explores metabolic reprogramming in cancer cells and the role of 2-HG in altering DNA methylation, angiogenesis, and immune evasion. Validated antibodies with high sensitivity and minimal cross-reactivity are critical for accurate experimental and diagnostic outcomes, supporting advancements in precision oncology.
×
